TABLE 3.
Treatments in the first 14 days after intensive care unit admission of nontransplant patients and solid organ transplant patients in the propensity score matched cohort
| Treatments | All patients (N = 386) | Non-SOT (N = 288) | SOT (N = 98) | P value |
|---|---|---|---|---|
| Antibiotics/antivirals – no. (%) | ||||
| Chloroquine | 3 (1) | 1 (0) | 2 (2) | .10 |
| Hydroxychloroquine | 258 (67) | 196 (68) | 62 (63) | .38 |
| Azithromycin | 199 (52) | 150 (52) | 49 (50) | .72 |
| Hydroxychloroquine and azithromycin | 307 (80) | 233 (81) | 74 (76) | .25 |
| Remdesivir | 26 (7) | 20 (7) | 6 (6) | .78 |
| Ribavirin | 1 (0) | 1 (0) | 0 (0) | .56 |
| Lopinavir/ritonavir (Kaletra) | 14 (4) | 11 (4) | 3 (3) | .73 |
| Therapeutic anticoagulation – no. (%)a | ||||
| Any | 176 (46) | 130 (45) | 46 (47) | .78 |
| Heparin drip | 132 (34) | 96 (33) | 36 (37) | .54 |
| Enoxaparin | 41 (11) | 35 (12) | 6 (6) | .09 |
| Bivalirudin | 4 (1) | 1 (0) | 3 (3) | .02 |
| Argatroban | 1 (0) | 1 (0) | 0 (0) | .56 |
| Anti-inflammatory medications – no. (%) | ||||
| Corticosteroids | 173 (45) | 109 (38) | 64 (65) | <.01 |
| NSAIDs | 13 (3) | 13 (5) | 0 (0) | .03 |
| Aspirin | 128 (33) | 94 (33) | 34 (35) | .71 |
| Statin | 132 (34) | 92 (32) | 40 (41) | .11 |
| Tocilizumab | 70 (18) | 47 (16) | 23 (23) | .11 |
| Other interleukin-6 inhibitor or interleukin-6 receptor inhibitor | 2 (1) | 1 (0) | 1 (1) | .42 |
| Vitamin C | 32 (8) | 28 (10) | 4 (4) | .08 |
| Other medications – no. (%) | ||||
| Convalescent plasma | 12 (3) | 7 (2) | 5 (5) | .19 |
| ACE-I | 12 (3) | 10 (3) | 2 (2) | .48 |
| ARB | 14 (4) | 11 (4) | 3 (3) | .73 |
| Tissue plasminogen activator | 5 (1) | 4 (1) | 1 (1) | .78 |
| Specific interventions for hypoxemia – no. (%) | ||||
| Neuromuscular blockade | 142 (37) | 105 (36) | 37 (38) | .82 |
| Inhaled epoprostenol | 18 (5) | 13 (5) | 5 (5) | .81 |
| Inhaled nitric oxide (iNO) | 22 (6) | 14 (5) | 8 (8) | .22 |
| Prone position | 126 (33) | 92 (32) | 34 (35) | .62 |
| Enrolled in a clinical trial – no. (%)b | 75 (19) | 55 (19) | 20 (20) | .79 |
Note: Each of the above interventions was assessed during the 14 days following ICU admission. All other variables had no missing data.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ICU, intensive care unit; N/A: not applicable; NSAIDs, nonsteroidal anti-inflammatory drugs; SOT, solid organ transplant.
a
Data on therapeutic anticoagulation were missing for 1 non-SOT patient (0.3%).
b
Data on enrollment in a clinical trial were missing for 1 non-SOT patient (0.3%).